Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract 1482: Tissue specific splicing program of hMENA: impact on tumor immune microenvironment in node-negative NSCLC

Francesca Di Modugno, Sheila Spada, Anna Di Carlo, Paola Trono, Isabella Sperduti, Barbara Antoniani, Enzo Gallo, Giulia Campo, Francesco Facciolo, Paolo Visca, Paola Nisticò

Cancer Res (2019) 79 (13_Supplement): 1482.

https://doi.org/10.1158/1538-7445.AM2019-1482

Published: 01 July 2019

View articletitled, Abstract 1482: Tissue specific splicing program of hMENA: impact on tumor immune microenvironment in node-negative NSCLC

Journal Articles

Abstract 5224: hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis

Francesca Di Modugno, Sheila Spada, Belinda Palermo, Paolo Visca, Pierluigi Iapicca, Anna Di Carlo, Barbara Antoniani, Isabella Sperduti, Anna Di Benedetto, Irene Terrenato, Marcella Mottolese, Francesco Gandolfi, Francesco Facciolo, Emily Chen, Martin A. Schwartz, Angela Santoni, Mina J. Bissell, Paola Nisticò

Cancer Res (2018) 78 (13_Supplement): 5224.

https://doi.org/10.1158/1538-7445.AM2018-5224

Published: 01 July 2018

View articletitled, Abstract 5224: hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis

Journal Articles

Abstract 3162: Endothelin-1 receptor/beta-arrestin-1 pathway promotes invadopodia and metastatic process by integration with hMENA in human serous ovarian cancer

Valentina Caprara, Francesca Di Modugno, Lidia Chellini, Piera Tocci, Francesca Spadaro, Andrea Sacconi, Giovanni Blandino, Paola Nisticò, Anna Bagnato, Laura Rosanò

Cancer Res (2018) 78 (13_Supplement): 3162.

https://doi.org/10.1158/1538-7445.AM2018-3162

Published: 01 July 2018

View articletitled, Abstract 3162: Endothelin-1 receptor/beta-arrestin-1 pathway promotes invadopodia and metastatic process by integration with hMENA in human serous ovarian cancer

Journal Articles

Abstract 4316: hMENA^11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells

Paola Trono, Francesca Di Modugno, Rita Circo, Sheila Spada, Roberta Melchionna, Belinda Palermo, Mariangela Panetta, Silvia Matteoni, Silvia Soddu, Ruggero De Maria, Paola Nisticò

Cancer Res (2015) 75 (15_Supplement): 4316.

https://doi.org/10.1158/1538-7445.AM2015-4316

Published: 01 August 2015

View articletitled, Abstract 4316: hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells

Journal Articles

Abstract A60: The hMENA Splicing Program: An important regulator of TGFβ1-driven EMT and invasiveness in pancreatic cancer

Roberta Melchionna, Pierluigi Iapicca, Francesca Di Modugno, Paola Trono, Novella Gualtieri, Maria Grazia Diodoro, Marcella Mottolese, Gian Luca Grazi, Matteo Fassan, Aldo Scarpa, Mina J. Bissell, Paola Nisticò

Cancer Res (2015) 75 (13_Supplement): A60.

https://doi.org/10.1158/1538-7445.PANCA2014-A60

Published: 30 June 2015

View articletitled, Abstract A60: The hMENA Splicing Program: An important regulator of TGFβ1-driven EMT and invasiveness in pancreatic cancer

Journal Articles

hMena and hMena^+11a cytoskeleton regulatory proteins and HER2 activity in breast cancer.

Francesca Di Modugno, Andrea Conidi, Michele Balsamo, Lucia DeMonte, Elisa Melucci, Duilia Del Bello, Giuliana Falasca, Barbara Antoniani, Massimo Alessio, Marcella Mottolese, Angela Santoni, Pier Giorgio Natali, Paola Nistico

Cancer Res (2008) 68 (9_Supplement): 5189.

Published: 01 May 2008

View articletitled, hMena and hMena+11a cytoskeleton regulatory proteins and HER2 activity in breast cancer.

Journal Articles

Epithelial to mesenchymal transition (EMT) and hMena splice variants expression are determinant of EGFR tyrosine kinase inhibitors (TKI) sensitivity in pancreatic adenocarcinoma (PDAC) cell lines

Maria Pino, Michele Balsamo, Francesca Di Modugno, David McConkey, Francesco Cognetti, Pier Giorgio Natali, Michele Milella, Paola Nistico

Cancer Res (2007) 67 (9_Supplement): 2995.

Published: 01 May 2007

View articletitled, Epithelial to mesenchymal transition (EMT) and hMena splice variants expression are determinant of EGFR tyrosine kinase inhibitors (TKI) sensitivity in pancreatic adenocarcinoma (PDAC) cell lines

Journal Articles

hMena^+11a is an epithelial-restricted hMena isoform which is phosphorylated along the pathway of ErbB tyrosine kinase receptors.

Francesca Di Modugno, Michele Balsamo, Giovanna Bronzi, Andrea Conidi, Lucia DeMonte, Massimo Alessio, John Condeelis, Frank Gertler, Angela Santoni, Pier Giorgio Natali, Paola Nistico

Cancer Res (2007) 67 (9_Supplement): 3814.

Published: 01 May 2007

View articletitled, hMena+11a is an epithelial-restricted hMena isoform which is phosphorylated along the pathway of ErbB tyrosine kinase receptors.

Journal Articles

Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena^+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena^+11a Phosphorylation in Breast Cancer Cell Lines

Francesca Di Modugno, Lucia DeMonte, Michele Balsamo, Giovanna Bronzi, Maria Rita Nicotra, Massimo Alessio, Elke Jager, John S. Condeelis, Angela Santoni, Pier Giorgio Natali, Paola Nisticò

Cancer Res (2007) 67 (6): 2657–2665.

https://doi.org/10.1158/0008-5472.CAN-06-1997

Published: 15 March 2007

View articletitled, Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines

Journal Articles

The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and in HER2 positive/hormonal receptor negative tumors

Marcella Mottolese, Francesca Di Modugno, Anna Di Benedetto, Flavia Novelli, Andrea Conidi, Letizia Perracchio, Irene Venturo, Ilaria Targa, Elke Jager, Angela Santoni, Pier Giorgio Natali, Paola Nisticò

Cancer Res (2006) 66 (8_Supplement): 842.

Published: 15 April 2006

View articletitled, The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and in HER2 positive/hormonal receptor negative tumors

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 1482: Tissue specific splicing program of hMENA: impact on tumor immune microenvironment in node-negative NSCLC

Abstract 5224: hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis

Abstract 3162: Endothelin-1 receptor/beta-arrestin-1 pathway promotes invadopodia and metastatic process by integration with hMENA in human serous ovarian cancer

Abstract 4316: hMENA^11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells

Abstract A60: The hMENA Splicing Program: An important regulator of TGFβ1-driven EMT and invasiveness in pancreatic cancer

hMena and hMena^+11a cytoskeleton regulatory proteins and HER2 activity in breast cancer.

Epithelial to mesenchymal transition (EMT) and hMena splice variants expression are determinant of EGFR tyrosine kinase inhibitors (TKI) sensitivity in pancreatic adenocarcinoma (PDAC) cell lines

hMena^+11a is an epithelial-restricted hMena isoform which is phosphorylated along the pathway of ErbB tyrosine kinase receptors.

Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena^+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena^+11a Phosphorylation in Breast Cancer Cell Lines

The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and in HER2 positive/hormonal receptor negative tumors

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only